All In Biotech

Drug Trial Radar · NCT04968574

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 19, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Aug 26, 2021

Primary completion

Nov 30, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
Endeavor Biomedicines, Inc.Industry
Sponsor type
Industry
First posted
Jul 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • taladegibDrug

    hedgehog pathway inhibitor dosed once daily

  • placeboDrug

    identical tablets to the experimental arm with no active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in frequency of adverse events (AEs)Time frame: Baseline to Week 18
  2. Change from baseline in severity of AEsTime frame: Baseline to Week 18
  3. Change from baseline in vital sign measurements - pulseTime frame: Baseline to Week 18
  4. Change from baseline in vital sign measurements - blood pressureTime frame: Baseline to Week 18
  5. Change from baseline in vital sign measurements - respiration rateTime frame: Baseline to Week 18
  6. Change from baseline in vital sign measurements - temperatureTime frame: Baseline to Week 18
  7. Change from baseline in blood oxygen saturation levelTime frame: Baseline to Week 18
  8. Incidence of clinical laboratory abnormalitiesTime frame: Baseline to Week 18
  9. Severity of clinical laboratory abnormalitiesTime frame: Baseline to Week 18
  10. Number of hospitalizationsTime frame: Baseline to Week 18

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Liverpool, New South Wales, Australia

  • Research Site

    Benowa, Queensland, Australia

  • Research Site

    Box Hill, Victoria, Australia

  • Research Site

    Clayton, Victoria, Australia

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Sherbrooke, Quebec, Canada

  • Research Site

    Batu Caves, Malaysia

  • Research Site

    Kota Bharu, Malaysia

  • Research Site

    Kuala Lumpur, Malaysia

  • Research Sire

    Kuala Lumpur, Malaysia

  • Research Site

    Kuala Lumpur, Malaysia

  • Research Site

    Chihuahua City, Mexico

  • Research Site

    Mexico City, Mexico

  • Research Site

    Mexico City, Mexico

  • Research Site

    Oaxaca City, Mexico

  • Research Site

    Puebla City, Mexico

  • Research Site

    Monterrey, Nuevo León, Mexico

  • Research Site

    Monterrey, Nuevo León, Mexico

  • Research Site

    San Nicolás de los Garza, Nuevo León, Mexico

  • Research Site (Namdong District)

    Incheon, South Korea

  • Research Site (Bundang District)

    Seongnam, South Korea

  • Research Site (Gangnam District)

    Seoul, South Korea

  • Research Site (Seongbuk District)

    Seoul, South Korea

  • Research Site (Songpa District)

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.